5 recruiting, 3 completed, 2 not yet recruiting, 1 active not recruiting. 13 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 13 | Recruiting 5, Completed 3, Not yet recruiting 2, Active not recruiting 1, Unknown 1, Withdrawn 1 |
Follow pembrolizumab: new trials by email Literature Review of pembrolizumab trials Research Report on pembrolizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44) Pembrolizumab, Cisplatin, 5-Fluorouracil - Neoplasm Malignant, Gastric Neoplasms | Phase 4 | Not yet recruiting | Merck Sharp & Dohme LLC | 150 | 2026-11-06 | 2026-09-03 |
| A Study of Treatment Delivery Preference In People With Kidney Cancer Nivolumab Injectable Product, Nivolumab, Pembrolizumab injection - Renal Cell Carcinoma, Kidney Cancer | Phase 4 | Recruiting | Memorial Sloan Kettering Cancer Center | 40 | 2026-09-24 | 2026-10-16 |
| Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study) Paclitaxel Oral Solution, PD-1/PD-L1 inhibitor (eg. Tislelizumab) - Squamous Non-Small Cell Lung Cancer sqNSCLC, Extensive-stage Small Cell Lung Cancer (ES-SCLC) | Phase 4 | Recruiting | Anhui Provincial Cancer Hospital | 107 | 2026-07-24 | 2026-08-04 |
| Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study Dabrafenib, Trametinib, Selpercatinib - Thyroid Neoplasms | Phase 4 | Not yet recruiting | Fujian Medical University | 335 | 2025-07-01 | 2025-06-08 |
| Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial Biospecimen Collection, Computed Tomography, Cystectomy - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma | Phase 4 | Recruiting | Mayo Clinic | 75 | 2025-01-08 | 2026-10-01 |
| Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma Atezolizumab, Nab paclitaxel, Carboplatin - Non-Small Cell Lung Cancer Metastatic | Phase 4 | Active not recruiting | Nikolaj Frost MD | 136 | 2023-12-06 | 2026-03-10 |
| Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie Nivolumab, Pembrolizumab, Ipilimumab - Oncology, Infusion Reaction | Phase 4 | Recruiting | Isala | 1082 | 2023-09-01 | 2026-10-29 |
| The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials Binimetinib, Encorafenib, Vemurafenib - Solid Tumors | Phase 4 | Recruiting | Pfizer | 210 | 2022-07-05 | 2026-10-19 |
| The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab Pembrolizumab - Newly Diagnosed Glioblastoma | Phase 4 | Unknown | Medical University of Silesia | 36 | 2022-03-01 | 2023-08-31 |
| A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10) Pembrolizumab, Carboplatin, Paclitaxel - Squamous Cell Carcinoma of Head and Neck | Phase 4 | Completed | Merck Sharp & Dohme LLC | 101 | 2020-10-27 | 2025-06-19 |
| Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma Pembrolizumab, Ciprofloxacin 500mg PO BID days 1-29, Metronidazole 500mg PO TID days 1-29 - Pancreatic Cancer | Phase 4 | Withdrawn | NYU Langone Health | 2019-06-25 | 2020-06-26 | |
| Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) Pembrolizumab - Carcinoma, Non-Small-Cell Lung, Melanoma | Phase 4 | Completed | Merck Sharp & Dohme LLC | 150 | 2019-01-31 | 2025-08-29 |
| Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX Pembrolizumab Injection - Metastatic Non-Small Cell Lung Carcinoma | Phase 4 | Completed | Samsung Medical Center | 50 | 2018-05-14 | 2024-12-03 |
Parkinson Disease 4, Autosomal Dominant Lewy Body (3) · Carcinoma, Non-Small-Cell Lung (2) · Neoplasms (2) · Carcinoma, Renal Cell (1) · Glioblastoma (1) · Kidney Neoplasms (1) · Melanoma (1) · Pancreatic Neoplasms (1) · Small Cell Lung Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1) · Thyroid Neoplasms (1) · Ureteral Neoplasms (1) · Urinary Bladder Neoplasms (1) · Uterine Cervical Neoplasms (1)
Merck Sharp & Dohme LLC (3) · Anhui Provincial Cancer Hospital (1) · Fujian Medical University (1) · Isala (1) · Mayo Clinic (1) · Medical University of Silesia (1) · Memorial Sloan Kettering Cancer Center (1) · NYU Langone Health (1) · Nikolaj Frost MD (1) · Pfizer (1) · Samsung Medical Center (1)
United States (5) · Australia (2) · Brazil (2) · Canada (2) · China (2) · Germany (2) · Netherlands (2) · South Korea (2) · Argentina (1) · Czechia (1) · France (1) · Greece (1) · Hungary (1) · India (1) · Israel (1)
Deidre Cohen (1) · Jacob J. Orme, MD, PhD (1) · Nikolaj Frost, PD Dr. (1) · Paras H. Shah, MD (1) · Sahil Doshi, MD (1) · Yueyin Pan, MD, PhD (1)
PMID 26028407, PMID 26291008, PMID 27413711, PMID 28196905, PMID 30280641, PMID 31590988, PMID 32599071, PMID 33333328, PMID 33538338, PMID 35576956, PMID 36166026, PMID 38460751, PMID 39038265
2023 (1)